Volume 49, Issue 5, Pages 781-789 (May 2006) Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?  David Cella, Daniel P. Petrylak, Mayer Fishman, Chris Teigland, Jay Young, Parvez Mulani  European Urology  Volume 49, Issue 5, Pages 781-789 (May 2006) DOI: 10.1016/j.eururo.2005.12.058 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 1 Time to disease progression in atrasentan trials: Data are shown from the meta-analysis (studies M00-211 and M96-594) intent-to-treat population and from the intent-to-treat and evaluable populations in a phase II trial (study M96-594) and a phase III trial (study M00-211). Data are presented as hazard ratio with 95% confidence intervals. ITT=intent-to-treat. European Urology 2006 49, 781-789DOI: (10.1016/j.eururo.2005.12.058) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 Mean QOL treatment difference between patients in the placebo group and 10mg atrasentan group using analysis of covariance. Data are shown from the meta-analysis as mean difference with 95% confidence intervals. QOL=Quality of Life. European Urology 2006 49, 781-789DOI: (10.1016/j.eururo.2005.12.058) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 3 Quality-adjusted time to disease progression for FACT-P and EORTC QLQ C-30 domains. In this phase III trial, patients were randomized to once-daily atrasentan 10mg or placebo and treated until disease progression. Data are presented as hazard ratio with 95% confidence intervals. FACT-P=Functional Assessment of Cancer Therapy-Prostate; PCS=Prostate Cancer Subscore; EORTC=European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). European Urology 2006 49, 781-789DOI: (10.1016/j.eururo.2005.12.058) Copyright © 2006 Elsevier B.V. Terms and Conditions